NetworkNewsBreaks

TuesdayAug 06, 2024 12:48 pm

NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) Submits New CNM-Au8 Biomarker, Clinical Efficacy Data to FDA

Clene (NASDAQ: CLNN), a late-stage biopharmaceutical company focused on protecting mitochondrial health and neuronal function to treat neurodegenerative diseases, and its wholly owned subsidiary Clene Nanomedicine Inc., have submitted new data to the U.S. Food and Drug Administration (“FDA”). The data is regarding CNM-Au8(R) biomarker and clinical efficacy information, including post hoc analyses from two phase 2 clinical trials of CNM-Au8 for the treatment of ALS; the trials were conducted independently. According to the announcement, this new data is in addition to original data the company has discussed with FDA and is intended to guide the planned FDA Type C interaction; that…

Continue Reading

TuesdayAug 06, 2024 12:36 pm

NetworkNewsBreaks – Astiva Health Announces Launch of Investor Relations Website to Facilitate Transparent, Effective Communication

Astiva Health, a leader in innovative and culturally aware healthcare solutions, today announced the launch of its new Investor Relations website. The launch marks a significant step and milestone in the company’s journey towards becoming a public company. It emphasizes Astiva Health’s commitment to maintaining transparent and effective communication and building strong relationships with investors, stakeholders, and the broader financial community. The platform will offer easy access to detailed company overviews and strategic vision, financial reports and performance metrics, press releases and media coverage, corporate government practices, and upcoming events and presentations. “We are excited to launch our Investor Relations…

Continue Reading

TuesdayAug 06, 2024 12:07 pm

NetworkNewsBreaks – Snap Inc. (NYSE: SNAP) Faces Downturn Despite Revenue Growth

Snap (NYSE: SNAP), the parent company of Snapchat, faced a significant downturn in its stock value during after-hours trading following its second-quarter earnings report for 2024. Despite a 16% year-over-year increase in total revenue, reaching $1.24 billion, the decline in the company’s stock reflects investor concerns about Snap’s future growth prospects, especially given the deceleration from the 21% growth recorded in the first quarter of 2024. The mixed financial results also highlighted a net loss of $249 million, which, despite being a 34% improvement from the previous year, still raises questions about the company’s profitability. Snap’s user engagement metrics, however, paint a more positive picture. The Daily Active…

Continue Reading

TuesdayAug 06, 2024 11:34 am

NetworkNewsBreaks – Blockchain Futurist Conference Plays Pivotal Role in Shaping the Future of Web3, Finance

Blockchain Futurist Conference is Canada’s largest and most high-profile Web3, blockchain and cryptocurrency event. Serving as an essential platform for ideas and collaboration, the conference has proven to be an important global gathering helping shape the future of Web3. This year’s event is scheduled for August 13-14, 2024, in Toronto, Canada; the event will run alongside ETHToronto and ETHWomen Hackathons, the largest web3 hackathons in Canada. During Futurist 2023, reporter Daniel Bruno solicited quotes from onsite attendees experiencing the excitement of the event. What they said sets the tone for this year’s dynamic must-attend Blockchain Futurist Conference. “We have attended…

Continue Reading

TuesdayAug 06, 2024 11:13 am

NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports on Clinical Data Showing Lead Compound Combined with GLP-1 Agonist Enhances Cognition

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting preclinical data regarding its lead compound, buntanetap. According to the announcement, the results show the synergistic effect of buntanetap when combined with the glucagon-like peptide 1 (“GLP-1”) agonist dulaglutide (Trulicity[R]) in a mouse model of Alzheimer’s disease. Based on data gathered in 2018 showing that buntanetap fully restored memory, learning and synaptic potentiation in an Alzheimer’s mouse model, Annovis recently studied whether buntanetap combined with the GLP-1 agonist dulaglutide produced a synergistic effect in the…

Continue Reading

TuesdayAug 06, 2024 11:09 am

NetworkNewsBreaks – Nightfood Holdings Inc. (NGTF) Expands into Growing Food-Service Segment with Recent Acquisition

Nightfood Holdings (OTCQB: NGTF), a forward-thinking acquisition and development holding company, has built a reputation in the sleep-friendly snack market. Now the company is expanding beyond the nighttime snack category into a growing segment of the food-service industry through recent acquisitions designed to diversify operations and capitalize on an emerging market. According to the article, Nightfood signed a letter of intent (“LOI “) to acquire SWC Group Inc., doing business as Carryoutsupplies.com, or CarryOut for short. CarryOut specializes in custom-printed food packaging and offers traditional and environmentally friendly selections for restaurants, cafes and other food-service businesses. “We are thrilled at…

Continue Reading

TuesdayAug 06, 2024 10:23 am

NetworkNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Shares Update from CEO

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today provided an update from CEO and chairman David Michery. According to the update, the company believes it has a strong foundation for future growth in EV sales based on the value of its total assets and cash position. Mullen highlighted the $250 million in new financing commitments it has secured to accelerate its growth plan, the expansion of its sales and distribution reach, the receipt of new orders, the delivery of vehicles, and negotiations to expand its customer base and market share. In addition, Mullen noted that it is…

Continue Reading

TuesdayAug 06, 2024 10:09 am

NetworkNewsBreaks – Ocugen Inc. (NASDAQ: OCGN) Closes on $35M Public Offering

Ocugen (NASDAQ: OCGN), a biotechnology company focused on discovering, developing and commercializing novel gene and cell therapies and vaccines, has closed on its previously announced underwritten public offering. The offering was comprised of 30,434,783 shares of its common stock, with each share sold at $1.15 per share. The company is anticipated to receive an estimated $35 million in gross proceeds, before standard deductions and expenses are made. Ocugen plans to use the funds from the offering for general corporate purposes, capital expenditures, working capital, and general and administrative expenses. Titan Partners Group, a division of American Capital Partners, acted as…

Continue Reading

MondayAug 05, 2024 3:14 pm

NetworkNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Preparing for NDA Submission for Leading Drug Candidate

PaxMedica (OTC: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is in the process of preparing to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”). The NDA is for PAX-101, an intravenous formulation of suramin that could potentially treat conditions such as Human African Trypanosomiasis and autism spectrum disorder (“ASD”). The process includes having a Type C meeting with the FDA, and then incorporating the outcomes of that meeting, which is a key opportunity for PaxMedica to demonstrate the therapeutic potential and public health benefits of PAX-101. “PaxMedica’s primary mission is…

Continue Reading

MondayAug 05, 2024 2:47 pm

NetworkNewsBreaks – Software Effective Solutions Corp. (d/b/a MedCana) (SFWJ) Focused on Building Framework to Strengthen Position in Growing Cannabis Sector

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ), a leading entity in the cannabis and agricultural technology sectors, is focused on solidifying its position in the growing cannabis market. According to a recent article, the global cannabis market, which reached an estimated $27.7 billion in 2022, is forecast to total $82.3 billion in 2027. MedCana is working on becoming the world’s premier resource for pharmaceutical cannabis products and playing a key role in that growing space. The company is currently involved in building technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts to the world. The…

Continue Reading